Randomized controlled phase III trial of weekly paclitaxel +/- ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018)

Rebecca Christian Arend,Bradley J. Monk,Ronnie Shapira-Frommer,Angeles Alvarez Secord,Thomas J. Herzog,Krishnansu Sujata Tewari,Jonathan A. Ledermann, Tamar Rachmilewitz Minei,Marc E. Buyse, Ashley Haggerty, Edwin A. Alvarez,Amnon Amit,Carolyn Muller,Antonio Casado Herraez,Laura L. Holman,Joshua Cohen,Marilyn Huang, Adelya Yachnin,Dror Harats,Richard T. Penson

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 0|浏览21

暂无评分

摘要

The addition of ofra-vec to paclitaxel did not improve PFS or OS. The PFS and ORR in the control arm exceeded the results that were anticipated on the basis of the AURELIA chemotherapy control arm. CA-125 response was a substantial prognostic biomarker for PFS and OS in patients with PROC treated with paclitaxel.

查看译文

关键词

paclitaxel,ovarian,cancer,phase iii trial,platinum-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要